Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MK-2118 |
Synonyms | |
Therapy Description |
MK-2118 is a STING agonist that may activate innate anti-tumor immune response (PMID: 33618600). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MK-2118 | MK2118|MK 2118 | STING1 Agonist 19 | MK-2118 is a STING agonist that may activate innate anti-tumor immune response (PMID: 33618600). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03249792 | Phase I | MK-2118 + Pembrolizumab MK-2118 | Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) in the Treatment of Adults With Advance/Metastatic Solid Tumors or Lymphomas (MK-2118-001) | Terminated | USA | ISR | 0 |